1383783-23-0

Upstream product

• 1383743-96-1 4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidine-1-carbonitrile 
• 1383740-03-1 5-cyclopropyl-4-((piperidin-4-yloxy)methyl)-3-(2-(trifluoromethoxy)phenyl)isoxazole 
• 1383740-02-0 tert-butyl 4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidine-1-carboxylate 
• 1383740-01-9 (Z)-N-hydroxy-2-(trifluoromethoxy)benzimidoyl chloride 
• 946427-86-7 4-(bromomethyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole 
• 94651-33-9 2-(trifluoromethoxy)benzaldehyde 

Downstream Products

• 1383783-24-1 methyl 4-((((amino(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)methylene)amino)oxy)carbonyl)benzoate 
• 1383743-66-5 methyl 4-(3-(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1,2,4-oxadiazol-5-yl)benzoate 
• 1383743-67-6 4-(3-(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1,2,4-oxadiazol-5-yl)benzoic acid 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS

The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).